The GETUG 14 trial showed that combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improved disease-free survival in men with intermediate-risk prostate cancer compared to radiotherapy alone. The study included 376 patients with localized prostate cancer and found that adding short-term ADT to high-dose radiotherapy resulted in a 36% relative improvement in 5-year disease-free survival. There was a significant benefit for intermediate-risk patients, but not for high-risk patients. The combination therapy did not increase genitourinary or gastrointestinal toxicities. Overall, the trial confirmed that short-term ADT improves disease-free survival in patients with intermediate-risk prostate cancer.
Source link
Adding ADT to High-Dose RT Benefits Some Prostate Cancers
